Author:
Bowman Katherine Redd,Lu Phong,Lim Carol
Abstract
AbstractRecent advances in liver cancer treatments have not changed the fact that the majority of patients will not survive the disease. In order to advance future liver cancer treatments, this work presents an exploration of various iterations of the liver cancer specific AFP promoter as well as the gene construct p53-Bad*. p53-Bad* is a mitochondrially targeted re-engineered p53 therapy that has shown previous success in a zebrafish HCC model. Both the most promising AFP promoter and p53-Bad* were packaged in an adenoviral delivery system and tested in vitro in liver cancer cell lines. Finally, mixed results for adenoviral p53-Bad* in vivo are presented, and this work suggests future modifications to study parameters in order to further explore the potential of p53-Bad* as a potential liver cancer therapeutic.
Publisher
Cold Spring Harbor Laboratory
Reference16 articles.
1. Hepatocellular carcinoma;Lancet,2022
2. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
3. Administration, U. S. F. a. D. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma. https://www.fda.gov/drugs/resources-informaon-approved-drugs/fda-approves-tremelimumab-combinaon-durvalumab-unresectable-hepatocellular-carcinoma (accessed 6/20/23).
4. p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma;Mol. Pharm,2023
5. p53-Bad: a novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy;Mol. Pharm,2019